An Open Label Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Eptinezumab (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Alder Biopharmaceuticals
- 17 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2017 According to Alder Biopharmaceuticals media release, data is expected in the first half of 2018
- 05 Jan 2017 Status changed from not yet recruiting to recruiting.